Cannabidiol for the treatment of cannabis use disorder: a phase 2a, double-blind, placebo-controlled, randomised, adaptive Bayesian trial

In first RCT of cannabidiol for cannabis use disorder (n=48), cannabidiol 400 mg and 800 mg were reported to safe and more efficacious than placebo at reducing cannabis use (400 mg increased abstinence from cannabis by 0.48 days per week and 800 mg by 0.27 days per week)


The Lancet Psychiatry